Eloralintide

Overview

Eloralintide (Eli Lilly code LY3841136) is an investigational, selective, long-acting amylin receptor agonist being developed for obesity and overweight. It is research-only and NOT FDA-approved as of July 2026. A 48-week Phase 2 trial published in The Lancet (November 2025) reported dose-dependent mean body-weight reductions of roughly 9.5% to 20.1% versus 0.4% for placebo, and the Phase 3 ENLIGHTEN program began in December 2025.

Mechanism of Action

Eloralintide is a 37-amino-acid amylin analog that selectively activates the human amylin-1 receptor (AMY1R — a calcitonin-receptor core paired with RAMP1), reported at roughly 12-fold greater potency than the calcitonin receptor and ~11-fold over AMY3R, with intentionally minimal calcitonin-receptor activity that distinguishes it from the non-selective cagrilintide. Amylin-receptor agonism promotes satiety and slows gastric emptying through brainstem signaling in the area postrema and nucleus tractus solitarius. Structurally, native amylin's Cys2–Cys7 disulfide is replaced by a methylene thioacetal bond for stability, and Lys26 is acylated with a two-γ-Glu linker plus a saturated C20 fatty diacid that enables reversible albumin binding — giving a terminal half-life of roughly 13–15 days that supports once-weekly subcutaneous dosing (molecular formula C201H319N49O65S2, MW ≈ 4526; vendor/COA listings cite CAS 2883634-40-8).

Research Summary

A Phase 1 single-ascending-dose program (NCT05295940) in healthy participants established proof of concept, and a 48-week Phase 2 trial in 263 adults with obesity or overweight (NCT06230523), published in The Lancet in November 2025, reported dose-dependent mean body-weight reductions of roughly 9.5% (1 mg) to 20.1% (9 mg) versus 0.4% for placebo, with mainly dose-dependent gastrointestinal adverse events. Eli Lilly is also studying eloralintide in combination with tirzepatide, and the Phase 3 ENLIGHTEN program (e.g. ENLIGHTEN-2, NCT07282600) began in December 2025. Eloralintide is not FDA-approved; grey-market use is research-only and not clinically validated.

Vendors selling Eloralintide

Scored vendors carrying Eloralintide, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Nausea (dose-dependent, most common adverse event class)
• Vomiting
• Diarrhea
• Fatigue
• Injection site reactions

Biomarkers researchers track for Eloralintide

These biomarkers appear in the research literature as measures of response and safety for this compound.

Related Peptides

Research References

• Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Molecular Metabolism. 2025. PMID 41109426.
• Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025 (NCT06230523; presented at ObesityWeek 2025).
• Bhattachar SN, et al. Pharmacokinetics and safety of eloralintide (LY3841136) in adults. Diabetes Obesity and Metabolism. 2026. PMID 41559929.
• American Diabetes Association 2025, abstract 882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist. Diabetes. 2025;74(Suppl 1).
• Eli Lilly and Company. What to know about eloralintide (company newsroom explainer).

Frequently asked questions

Has Eloralintide been independently lab-tested?

Disclosed Labs has collected 1 Certificate of Analysis (COA) for Eloralintide from 1 independent testing lab. 1 vendor has submitted material for testing. Products average 99.9% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/eloralintide/testing.

Where can researchers source Eloralintide?

1 vendor with Disclosed Labs trust grades currently list Eloralintide, including Peptide Plugs. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/eloralintide.

How does Eloralintide work?

Eloralintide is a 37-amino-acid amylin analog that selectively activates the human amylin-1 receptor (AMY1R — a calcitonin-receptor core paired with RAMP1), reported at roughly 12-fold greater potency than the calcitonin receptor and ~11-fold over AMY3R, with intentionally minimal calcitonin-receptor activity that distinguishes it from the non-selective cagrilintide. Amylin-receptor agonism promotes satiety and slows gastric emptying through brainstem signaling in the area postrema and nucleus tractus solitarius. Structurally, native amylin's Cys2–Cys7 disulfide is replaced by a methylene thioacetal bond for stability, and Lys26 is acylated with a two-γ-Glu linker plus a saturated C20 fatty diacid that enables reversible albumin binding — giving a terminal half-life of roughly 13–15 days that supports once-weekly subcutaneous dosing (molecular formula C201H319N49O65S2, MW ≈ 4526; vendor/COA listings cite CAS 2883634-40-8).

What does the research say about Eloralintide?

A Phase 1 single-ascending-dose program (NCT05295940) in healthy participants established proof of concept, and a 48-week Phase 2 trial in 263 adults with obesity or overweight (NCT06230523), published in The Lancet in November 2025, reported dose-dependent mean body-weight reductions of roughly 9.5% (1 mg) to 20.1% (9 mg) versus 0.4% for placebo, with mainly dose-dependent gastrointestinal adverse events. Eli Lilly is also studying eloralintide in combination with tirzepatide, and the Phase 3 ENLIGHTEN program (e.g. ENLIGHTEN-2, NCT07282600) began in December 2025. Eloralintide is not FDA-approved; grey-market use is research-only and not clinically validated.